newsfilter
← Latest News
Business Wire·

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott